Lumateperone Ranks Highest Among Adjunctive MDD Therapies in First Network Meta-Analysis

Johnson & Johnson has announced findings from the first network meta-analysis (NMA) comparing lumateperone (Caplyta) with other FDA-approved atypical antipsychotics used as add-on treatment for adults with major depressive disorder (MDD). Presented as a late-breaking poster at the 2026 Neuroscience Education Institute (NEI®) Spring Congress in Kissimmee, Florida, the analysis found lumateperone ranked highest across 4 key efficacy measures and demonstrated a favorable tolerability profile, particularly with respect to weight, when compared with the other agents evaluated.^1,2

The network meta-analysis drew on data from 10 registrational randomized controlled trials.² Among the trials were 2 for lumateperone (studies 501 and 502), 3 for aripiprazole, 2 for brexpiprazole trials, 2 for cariprazine, and 1 for quetiapine XR. Because no head-to-head trials exist among these agents, the network meta-analysis used a star-shaped network of 5 treatment nodes, each anchored to placebo plus antidepressant therapy, to generate indirect comparisons.

Lumateperone was approved as an adjunctive therapy for MDD in November 2025, based on 2 pivotal phase 3 trials.³

Efficacy Findings

Across all 4 efficacy outcomes evaluated (Montgomery-Åsberg Depression Rating Scale [MADRS] change from baseline, MADRS response, MADRS remission, and Clinical Global Impression–Severity [CGI-S] change from baseline), lumateperone demonstrated the largest effect size among the 5 treatment nodes. Specific results included a mean difference of -4.71 points on MADRS change from baseline (95% credible interval [CrI]: -5.78, -3.63), an odds ratio of 2.33 for MADRS response (95% CrI: 1.77, 3.05), an odds ratio of 2.22 for MADRS remission (95% CrI: 1.57, 3.07), and a mean difference of -0.60 on CGI-S change from baseline (95% CrI: -0.74, -0.46).²

In pairwise comparisons anchored to lumateperone, the drug was favored over all comparators for MADRS and CGI-S change from baseline, and over all but one comparator for MADRS response and remission.²

"This analysis is valuable because it gives us indirect comparative insights in a space where we don't have head-to-head trials, which may inform treatment discussions in everyday clinical practice," said Andrew J. Cutler, MD, the lead author of the analysis, chief medical officer of the Neuroscience Education Institute, and clinical professor of Psychiatry at SUNY Upstate Medical University. "The findings suggest adjunctive lumateperone has a high likelihood of helping patients achieve meaningful improvement in symptoms. Symptom improvement is an important step toward remission, the ultimate goal of treatment."¹

Safety and Tolerability

On weight-related outcomes, lumateperone demonstrated no statistically significant weight gain compared with placebo plus antidepressant therapy, with a mean weight change from baseline of -0.08 kg (95% CrI: -0.30, 0.13) and a 77% probability of superiority over placebo plus antidepressant therapy. It also showed a 94% probability of lower risk for clinically meaningful weight gain of ≥7% body weight compared with placebo plus antidepressant therapy, and a 100% probability of superiority over all comparators on mean weight change.

On akathisia, lumateperone was the only agent among those evaluated that was statistically comparable with placebo plus antidepressant therapy (OR 3.78; 95% CrI: 0.40, 17.17), while all 4 remaining treatments showed higher akathisia risk than placebo plus antidepressants. Somnolence risk was elevated above placebo plus antidepressants across all 5 treatments, including lumateperone (OR 5.90; 95% CrI: 2.86, 11.50); in pairwise comparisons, lumateperone showed comparable somnolence risk vs 2 agents and higher risk vs 2 others.²

"The adjunctive treatments approved for MDD share a common indication but differ in their pharmacologic profiles, efficacy, and tolerability," Leonardo Diaz, MD, vice president of US Medical Affairs for Caplyta at Johnson & Johnson, said in a press statement. "This [NMA] provides indirect comparative evidence derived from placebo-controlled studies that may help inform treatment decisions, reinforcing the role of Caplyta as an important treatment option for the many adults with MDD who do not achieve adequate symptom control with an antidepressant alone."¹

Methodology and Limitations

A network meta-analysis is a structured, protocol-driven analytical method accepted by regulatory agencies, health technology assessment bodies, and medical guideline committees as a means of comparing treatments when direct head-to-head data are unavailable. In this analysis, doses were pooled within treatments to reflect clinical decision-making at the treatment level. Outcomes were selected based on data availability across the identified trials.

Because network meta-analyses rely on indirect comparisons across studies that may differ in design and patient populations, findings should be interpreted cautiously alongside the totality of evidence, including individual trial results and clinical considerations, the poster authors noted. Additional safety and tolerability outcomes were not assessed in this network meta-analysis due to inconsistent reporting across trials.

"The goal of treating patients with MDD should be remission of symptoms, which may mean adding to their current treatment in order to achieve the best outcomes," said Cutler, framing the analysis within the broader treatment goal.¹

Lumateperone investigator, Suresh Durgam, MD, discussed the potential of this treatment for patients with MDD⁴ with Psychiatric Times: “Despite treatment, 2 in 3 patients continue to experience lingering symptoms of depression, significantly impacting their quality of life. For patients who are experiencing partial relief from their oral antidepressants, adding Caplyta to their treatment plan can build on the benefit they are already receiving and offer hope that complete relief is possible.”

References

1. CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis. News release. May 4, 2026. Accessed May 4, 2026. https://www.jnj.com/media-center/press-releases/caplyta-lumateperone-showed-greatest-improvement-across-key-efficacy-outcomes-among-adjunctive-mdd-treatments-in-new-network-meta-analysis

2. Cutler AJ, Lemyre A, Zhang Q, et al. Efficacy and safety of lumateperone versus atypical antipsychotics as adjunctive therapy in major depressive disorder: a pooled-dose network meta-analysis. Poster presented at: 2026 NEI® Spring Congress; May 1–3, 2026; Kissimmee, FL. https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2026/nei-spring/efficacy-and-safety-of-lumateperone-versus-atypical-antipsychotics-as-adjunctive-therapy-in-major.pdf

3. Kuntz L. FDA approves Caplyta for adjunctive treatment of major depressive disorder. Psychiatric Times. November 6, 2025. https://www.psychiatrictimes.com/view/fda-approves-caplyta-for-adjunctive-treatment-of-major-depressive-disorder

4. Kuntz L, Durgam S. Lumateperone as an adjunctive therapy for MDD: in conversation with the primary investigator. Psychiatric Times. November 12, 2025. https://www.psychiatrictimes.com/view/lumateperone-as-an-adjunctive-therapy-for-mdd-in-conversation-with-the-primary-investigator

The articles and interviews featured on this page were developed by Psychiatric Times editorial staff and contributors based on presentations delivered at NEI® Congress, an annual conference produced by HMP Global. Psychiatric Times is an independent publication and is not affiliated with, endorsed by, or sponsored by any third-party. All content on this page reflects the independent editorial judgment of Psychiatric Times and does not represent the views, positions, or communications of any third-parties.